

Review of: "mRNA: vaccine or gene therapy? Regulatory issues."

Vikas Maharshi

Potential competing interests: No potential competing interests to declare.

Topic chosen is enlightening to the stakeholders and stimulates critical thinking. Only USFDA and EMA have been taken into consideration. Any other regulatory agencies having regulations for nucleic based products might also have been referred to, if any. The heading, why regulatory bodies did not review the mRNA vaccines thoroughly, is written after conclusion, which might have been written before it and with more humble title that does not point out regulatory bodies directly, because this is author's view and knowledge only, need not to be true in absolute sense. So, criticism should be there but in professional way.

Overall topic is worth with some corrections in language, punctuations and expanding the abbreviations.